July 24, 2023 10:33 AM EDTUpdated 02:02 PM
R&D

Bio­Car­dia paus­es en­roll­ment in PhI­II tri­al of heart fail­ure stem cell ther­a­py

Lei Lei Wu

News Reporter

Bio­Car­dia has paused en­roll­ment in a piv­otal study of its stem cell ther­a­py for heart fail­ure af­ter an in­de­pen­dent re­view board de­ter­mined the tri­al was …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times